Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JB-101
- Development stage
- Phase 2
- Lead developer
- Junten Bio
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
JB-101 is an autologous cell therapy consisting of induced inhibitory T cells (iTS) developed by RegCell Co., Ltd., a biotechnology company spun out of Kyoto University. The therapy is designed to induce operational tolerance in patients undergoing living-donor liver transplantation (LDLT), with the ultimate goal of allowing for the complete withdrawal of lifelong immunosuppressive medication. JB-101 cells are generated ex vivo from the recipient's own T cells and are induced to function as regulatory-like cells that suppress the immune system's rejection of the transplanted organ. By reintroducing these specialized cells into the patient, the treatment aims to modulate the immune environment to accept the donor liver as self while preserving the patient's ability to fight infections.
- Other names
- induced inhibitory T cellsiTSinducible inhibitory T cellsautologous induced inhibitory T cells
Beyond the preview
Go deeper on JB-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JB-101.